What are the most anticipated and perhaps most lucrative approvals for 2022? In this case, the targets range from psoriasis and lung cancer to Alzheimer's illness and diabetes. And by the middle of the decade, the top 10 most anticipated pharmaceuticals are expected to generate a combined $26.9 billion in revenue, according to the life sciences data crunchers at Evaluate Vantage. The FDA approved 55 new drugs last year, and biopharma and the American agency are still working nonstop to provide new treatments to patients. In this case, the targets range from psoriasis and lung cancer to Alzheimer's illness and diabetes. And by the middle of the decade, the top 10 most anticipated pharmaceuticals are expected to generate a combined $26.9 billion in revenue, according to the life sciences data crunchers at Evaluate Vantage.
The Present Scenario
The FDA approved 55 new drugs last year, and biologics pharmaceutical CDMO and the American agency are still working nonstop to provide new treatments to patients. The top two pharmaceutical companies stand to make just under $11 billion from their respective proposed diabetes and Alzheimer's treatments, respectively, in 2022, giving Eli Lilly a very successful year. The top 2 expected medicine launches of the year are listed below. The 2017 edition is available here. Please share your opinions on these medications and any upcoming medications you believe we overlooked. Managing regulatory affairs can be challenging.
Donanemab
Drug: DonanemabCompany: Eli LillyUsed for: Alzheimer's diseaseEst. 2026 sales: $6 billion On Evaluate Vantage's list of the highest-grossing potential releases for the most widely anticipated pharmaceuticals of the year, an Alzheimer's disease treatment comes first again. That distinction was awarded to Biogen's aducanumab, an amyloid treatment approved in June under the brand name Aduhelm. Evaluate predicted the drug's peak sales to be around $4.8 billion in 2026. Eli Lilly will grab the top spot this year as Evaluate targets sales of a beefier $6 billion for its Alzheimer's candidate donanemab. Donanemab is an anti-amyloid beta monoclonal antibody like Aduhelm, but Lilly hopes to outperform its rival and increase market share. 
Tirzepatide
Drug: TirzepatideCompany: Eli LillyUsed for: DiabetesEst. 2026 sales: $4.9 billion Eli Lilly struck twice on our list of the most anticipated drug launches of the year. Donanemab, a drug for Alzheimer's disease, came in first and is anticipated to generate $6 billion in sales by 2026. Tirazepatide, a drug for diabetes, came in second and is anticipated to generate $4.9 billion by the middle of the next decade, according to Evaluate Vantage. Given its lengthy experience in diabetes, Lilly has a considerably more stable market area here than it does with Alzheimer's. And, much like its competitive life in this condition, it is facing up against Novo Nordisk of Denmark. Over the past few years, tirzepatide, a dual GIP and GLP-1 agonist has been dominating trials and helping Type 2 diabetes patients control their blood sugar levels and weight. Its biggest victory came in a direct head-to-head study against Novo Nordisk's GLP-1 juggernaut Ozempic last year.
Reviewed by